Endometrial Ablation Market Analysis & Forecast to 2024-2034

The global endometrial ablation market size was estimated to be USD 1.20 billion in 2023 and is expected to reach at USD 2.24 billion by 2034 with a CAGR of 5.84% during the forecast period 2024-2034. Surge in prevalence of gynaecological disorders such as PCOD & menorrhagia, growing awareness regarding the procedure among population, rising number of patients affected by menorrhagia, increasing initiatives by governments & private organizations for Women’s health, surge in strategic initiatives such as partnerships, collaborations, mergers, & acquisitions within market players, growing approvals of advanced devices by regulatory bodies, rising technological advancements, and increasing introduction of advanced endometrial ablation devices are some of the key factors boosting the market growth.

Increasing introduction of advanced endometrial ablation devices is predicted to boost the market growth during the forecast period. Endometrial ablation is a medical procedure designed to remove the endometrial lining from the uterine wall. This process involves the destruction of the thin endometrial layers, which helps in stopping abnormal and heavy uterine bleeding. It is often recommended when uterine bleeding can no longer be effectively managed with medications. As a result, industry participants are prioritizing the development of innovative and technologically advanced devices. For instance, in January 2022, Inovus Medical has introduced HystAR, a new high-fidelity hysteroscopy simulator. HystAR joins Inovus' existing hysteroscopy simulator lineup, including the well-established Bozzini Hysteroscopy series that has been available on the market for several years.

By product, radiofrequency ablation was the highest revenue-grossing segment in the global endometrial ablation market in 2023 owing to its convenience, quick treatment, effectiveness, cost-efficiency, & readily accessible and surge in approvals by regulatory bodies. For instance, in February 2023, Hologic Inc. has received approval for the NovaSure V5 global endometrial ablation (GEA) device in both Canada and Europe. Additionally, others is predicted to grow at fastest CAGR during the forecast period owing to the growing number of medical procedures, including hysterectomies and surge in introduction of advanced systems.

By end-user, clinics was the highest revenue-grossing segment in the global endometrial ablation market in 2023 owing to the surge in awareness regarding the use of endometrial ablation devices, growing clinical trials focused on endometrial ablation techniques, rising government funding allocations for the broader accessibility of healthcare devices, and increasing adoption of innovative technologies. For instance, in October 2022, Channel MedSystems has reported that the initial procedures in Europe involving the Cerene Cryotherapy device for addressing heavy menstrual bleeding were conducted at Bergman Clinics in Amsterdam. Additionally, hospitals is predicted to grow at fastest CAGR during the forecast period owing to the surge in the hospitalization of patients for gynecological disorders, with hospitals offering high-quality care & reimbursement options, and rising adoption of advanced treatment devices by hospitals.

North America region is anticipated for the highest revenue share during the forecast period owing to the growing prevalence of gynaecological disorders, increasing preference for minimally invasive surgical procedures, rising investment by major market players, and surge in collaborations within market players. For instance, in February 2022, CooperSurgical has agreed to invest $875 million in Cook Medical's reproductive health portfolio, encompassing fertility, obstetrics, gynecology, and in vitro fertilization medical equipment. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of menorrhagia, increasing demand for innovative technology, surge in healthcare expenditure, growing awareness regarding women’s healthcare technologies, and rising approvals by regulatory bodies. For instance, in December 2022, Two RF Medical ablation systems, Mygen M-3004 and Myoblate, have obtained FDA marketing clearance for treating damaged tissue and tumors. Mygen M-3004 produces radiofrequency (RF) energy using compatible electrodes to eliminate abnormal tissue, focusing on lesions of various shapes and sizes.

Segmentation: Endometrial Ablation Market Report 2023 - 2034

Endometrial Ablation Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)

• Hydrothermal Ablation
• Radiofrequency Ablation
• Microwave Energy
• Thermal Balloon
• Cryoablation
• Others
• Hysteroscopes
• Electrical Ablators
• Resectoscopes

Endometrial Ablation Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)

• Ambulatory Surgical Centers
• Clinics
• Hospitals

Endometrial Ablation Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of LATAM
• Middle East & Africa
• South Africa
• GCC
• Rest of MEA